Wuxi No. 4 People's Hospital
11
1
1
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 11 trials
100.0%
+13.5% vs industry average
18%
2 trials in Phase 3/4
33%
1 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
18F-FDG PET/CT in the Diagnosis of Tuberculous Pericarditis
Role: lead
A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer
Role: collaborator
Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15)
Role: collaborator
Safety Study of 89Zr-Anti-CLDN18.2 mAbs PET Imaging in Patients With CLDN18.2 Positive Solid Tumors
Role: lead
Safety Study of 89Zr-NY001 PET Imaging in Patients
Role: lead
89Zr-labeled KN035 PET Imaging in Patients With PD-L1 Positive Solid Tumors
Role: lead
Clinic Study of 18F-Al-NOTA-MATBBN in Cancer Diagnostics
Role: lead
Clinic Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics
Role: lead
Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer
Role: collaborator
Effects of HFNC on Moderate and Severe Respiratory Failure Patients
Role: collaborator
The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment
Role: collaborator
All 11 trials loaded